-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 V1VWiv5apHB5wlshoiwXiytQ8RysUJgi3vNKhDdwzQBgSBF1+c1opxT48pfkjiK8
 FOn/mzxHNfVeNN7g+gs5pA==

<SEC-DOCUMENT>0001144204-08-047948.txt : 20080815
<SEC-HEADER>0001144204-08-047948.hdr.sgml : 20080814
<ACCEPTANCE-DATETIME>20080815163456
ACCESSION NUMBER:		0001144204-08-047948
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080814
FILED AS OF DATE:		20080815
DATE AS OF CHANGE:		20080815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		081023254

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v123616_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      month of August, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      X
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      X
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated August 14,
      2008
      is hereby incorporated by reference into the registration statements on Form
      F-3
      (File No. 333-141529 and File No. 333-147024) filed by XTL Biopharmaceuticals
      Ltd. with the Securities and Exchange Commission on March 23, 2007 and October
      30, 2007, respectively, and the registration statements on Form S-8 (File No.
      333-148058 and File No. 333-148574) filed by XTL Biopharmaceuticals Ltd. with
      the Securities and Exchange Commission on December 14, 2007 and January 18,
      2008, respectively.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace
      Rule Due to Changes in Board Composition </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, NY, August 15, 2008</strong> - XTL Biopharmaceuticals Ltd. (NASDAQ:
      XTLB, TASE: XTL) announced today the receipt of a Staff Deficiency Letter from
      The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) indicating that the Company fails to comply
      with the audit committee composition requirements of Nasdaq Marketplace Rule
      4350(d)(2), which requires XTL to maintain an audit committee comprised of
      at
      least three independent directors. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL,
      an
      Israeli domiciled company, is required by the Israeli Companies Act to elect
      two
      External Directors to the Company&#8217;s Board of Directors, each to serve a
      three-year term. XTL&#8217;s last External Directors were appointed on August 1, 2005,
      and their term expired on July 31, 2008. The Israeli Companies Act requires
      further that XTL&#8217;s audit committee consist of three directors and that both
      External Directors be members of the audit committee. As a result of the
      expiration of the External Directors&#8217; term of office on July 31, 2008, and the
      fact that new External Directors have yet to be elected, XTL does not currently
      have a valid Audit Committee under the Israeli Companies Act and consequently
      does not comply with Nasdaq Marketplace Rule 4350(d)(2).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      has
      commenced a process to identify qualified replacements to fill the two External
      Director vacancies, and expects to complete this process and provide evidence
      of
      its compliance with the Marketplace Rules to Nasdaq in short order. Until that
      time, the&#160;Company's Board of Directors, comprised of five directors, one of
      whom is a financial expert, and four of whom are considered by XTL to be
      independent directors under the Securities Exchange Act of 1934 and applicable
      listing rules of Nasdaq, will assume, for the purposes of corporate governance
      matters, the duties of the audit committee to the extent permitted.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">-2-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of diabetic neuropathic pain and HCV. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has
      out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL
      also has an active in-licensing and acquisition program designed to identify
      and
      acquire additional drug candidates. XTL is publicly traded on the NASDAQ and
      Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating the continued uninterrupted trading of the Company&#8217;s ADRs on the
      NASDAQ Capital Market and the Company&#8217;s ability to maintain compliance with
      NASDAQ Capital Market listing requirements, may be forward-looking statements
      that involve a number of risks and uncertainties. For those statements, we
      claim
      the protection of the safe harbor for forward-looking statements contained
      in
      the Private Securities Litigation Reform Act of 1995. Risk factors that could
      adversely affect our operations are identified from time to time in our reports
      filed with Securities and Exchange Commission, including our annual report
      on
      Form 20-F filed with the Securities and Exchange Commission on March 27, 2008.
      Any forward-looking statements set forth in this press release speak only as
      of
      the date of this press release. We do not intend to update any of these
      forward-looking statements to reflect events or circumstances that occur after
      the date hereof. This press release and prior releases are available at
      http://www.xtlbio.com. The information in our website is not incorporated by
      reference into this press release and is included as an inactive textual
      reference only.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">-3-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
                BIOPHARMACEUTICALS LTD.</strong></font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                August 15, 2008</font></div>
            </td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
              Bentsur</font></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
                Bentsur</font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer</font></div>
            </td>
          </tr>

      </table><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">-4-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0V@17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P.#HP.#HQ
M-"`Q,#HS-#HS,0```````Z`!``,````!``$``*`"``0````!````J*`#``0`
M```!````2``````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```QJ````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`10"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]50<W+IPL._,OD4XU;[;($G:QIL?M']5
MJY_Z^T=<_8YZAT3+NQ\C!W66TTD?I:3_`#WM<UWZ:G;ZM7_7:_\`"+SCI?UT
MZK]K;7UK.MS.DY378^=6\C^9N'IOOK]-F[?3N]7V_F*7'A,X\0.VX_28YY!$
M@'KL78;_`(W>L?;?6=A8_P!@F3C@O];9_P"&=WI>K_Z#[/\`JUZABY-67BTY
M5!W4Y#&VUNXEKP'L/^:Y>7_^-+U`94/ZC0.ECW')@BWT^?H?S#7[/\+ZOIK'
MZK]=^K.S+/V/FVX/2<=K:<*FN(%%0].NQWJ,<_?=M]3_`,#4LL4,E#%6GS+!
M.4+]SJ='VU)>>95GUFZ1_B^R.J=0ZC>.J9+J+&EQ`-%;K:V,I'M_G7U/_6/^
MV_\`!KB/^>WUG_\`+F_[V?\`I-1QY<RNI#0TOEE$:L'5]Z27A`^N7UK(D=7R
M"#WEG_I-1/UU^M`,'K&0".02S_TFG?=)]PM^\1[%]Y27@[?KI]:7?1ZQD&/`
ML_\`2:[7_%AUSK'4\_J%?4<RW+9554ZL6$0"YUH<1M:W]U-GR\H1,B1HF.:,
MCPT7T-))!S'.9B7N82US:WEKAR"&G50@6:9":!/9,DN6^I'4<_..9]LO??Z8
MJV;XTW>KNB!^=M74I^7&<<S`FR*V\?4QX,PS8XY(@@2O?^J>%222Y?ZUN^L(
MS*?V3]H]+TCO]$`MW;N_\O:ECAQR$;$;ZRV3FR^U`SX3.OT8:R>H24*MWIMW
M3N@3/,PIIC(I))))3__0]57B?U[^K7[`ZR[T&1T[.W6XL<,/^'Q?^MN.^O\`
MX%Z]L7,_XQ6=+=]5<D]1);L+78A;&_[1Q0*P?I;O=ZO_`'7]92X)F,QVEH6/
M+`2B?#4/GC_KKF/^IC/J[+O7#O0??XX0$LIW3_._]I'_`/=1G_"(_P#B[^K!
MZSU7[?E,GIW3W!Q!'MMO'OJI_E,I_GKO^M+DC,:<_P`5[A]1;>E6?5?"_93=
ME+&[;6.(+Q<#^L^M'^$=;[_ZG\A6<Q]N!X17&=2PXOUD@9'Y1H'><UKA#@'#
MP.JCZ-7[C?N"FDJ+:?"/K=_XJ^K?^&7?]2Q>L?4>NMWU1Z27-!/V9FI`7D_U
MN_\`%7U;_P`,N_ZEB]:^HW_B0Z3_`.%F*WS'\U#Z?DU\/\Y-YO\`QO-:WIG3
M=K0/UIW`C_!/5#_%!_REU3_B*?\`J[EH_P"-_P#Y,Z;_`.&G?^>K%G?XH/\`
ME+JG_$4_]7<@/]S'^7Z23_/CR?4$#._H61_Q3_\`J2CH&=_0LC_BG_\`4E5H
M[CS99_*?(O"_5;K.-T?%S\B_W/<*6TT@PY[AZW^:QG^$L5M_UR^L`'VC["QN
M,=0YU=L1_P`?N:S_`**I?4SI]69U3?<T/KQ:_4#3J"\D-KG^K[WKT-7N9GBA
ME-X_<E*C+B-5I\L7+Y''GR<O&LIPPCQ"'"+,O5Q<4K<;H/UFQNKS46^AE-&X
MU$[@X?OU/]N[^4A?6+ZRV]&R*:68[;Q:PODO+8@AO[KESG6ZF]#^LM=^*/3K
MEF0UC=``XEE]8_D/VV?YZL_7_P#IV)_Q3O\`JVH1P8SFQD"\>6)EPGH0/E72
MYO,.7S`D#-@E&!D!\T9'25/:/OKJH=?<X5UL;N>XF`!$E<IE?7?)NR/0Z/B&
M[]USVN<YP'YS<>F'-;_6>I?7K-?7AXN$TD,NFRV.[:PW8W_/=O6O]6NEU].Z
M74-H&1>UMN0_N7.&X,G]VIIV-44(8\>(99QXS,D0AL-/TBS9,F7+G.#%+VXX
MP)9<E<4KE\L(N)5]=>I8MXKZM@[`=88U]3P/WFUY!=ZG^?6NKQ,O'S<=F3C/
M%E-@EKA^(/[KF_G(/5>FT=3PK,6X#W":W]V/'T+&_P!5<M]1,NVO,R>GO/M>
MTVAO86,(JM_[<:YG_;:)CCRXI3A'@GCKBB/EE$JC/+@SPQ9)^[CRWP3(J<9Q
M_1D__]'U5>+?7WZS_M[JYKQWSTW`+F8Y'#W_`$;\K^KIZ='_``7Z3_"KN/\`
M&/UW,P^F_LKIM5UF7GM(MMI8YWI4?1L.YC7?I;_YFO\`Z[9_HUP7U2^J>5UG
MK5.-E8UM.!3^ERS8Q]8-;3[<=I>UG](?^C_XGUE9Y>(B#DETV8,Q)(A'KN6=
MOU+S*_J;7]8R'>JY_JOH\,-PVU7[8_G-WZR__NI9_P`$B?4#ZS?L+K`Q\E^W
MIW4'-KO)XKM^C1D_R6_X*_\`D?I/\$O9'U5OJ=2]@=4YI8YA`+2TC:6%O[NU
M>'?67ZJYO1NKWX%./=?B'WXMC*WV`TN^C6Y[&N_24_S+_P#MQ/QY!E$H3ZZC
M^7]5$X>V8R@-M"^Z)+DO\7?7<S/Z5^S^I5VUYN``P/M8YGJT_1IMW6-;NL9_
M,W?]N_X5=:JDHF,B#T9P;%OA'UN_\5?5O_#+O^I8O6OJ-_XD.D_^%F+ROZV8
M.>_ZT]5?7BWO8[)<6N;4]P(AG#FL7JWU)8^OZI]*98TL>W'8'-<""#YM<K.<
MCVX?RZ,.$'CF\W_C?_Y,Z;_X:=_YZL6=_B@!_:/5#V]"G_J[EJ?XVL?(OZ;T
MX4567%N2XD5L<\@>F\?F!R\YHHZWCDNQJ<V@N$.-3+F$@=G;&MW)V./%@X;J
M_P"*,A,<O%1.G1^@D#.UPL@#_1/_`.I*\)]3ZS_O=2_]F$[7_68N:"[J1:7-
M#@?M$$$C=/\`931RU$>L*EGL$<$MGT;_`!?O8,G+8?I.KK<WX-+P[_JV+MEY
MMTO%ZSBOLZE@TOWXCFBRHL=+F/W;OT?M]6OV?I-GZ1G\XM9_^,!YJ+680&1P
M-UDM#OZ@8U[OZBEYGEYY,IECJ6PEK\A:/(\YCP\O&&:\9U,;C+UQXNE-7ZZ1
MD]?JQZ_<_P!*NDM'[SWO+6_YMC47Z_\`].Q/^*=_U;47ZN=$S\WJ7[:ZJUPA
MWJ5BP;7/L_,?Z?\`@Z:O\%_8_P`&H_7RFZS-Q376^P"ITEC2[\]O[H3H2B,V
M'&"#[49"1Z<4AJQY(3/+\QF,3'WYQE&)^;@C+TZ+?7ZI^_"M@[75/9Y2-KO^
M_+K>G7LR,#&OK,LLJ8X?-H57K/2*^K=-.,2&6MA]%A_->!W_`)+OH/7*8'6N
MK?5DG!SL8NHDEC'G;!.KOL]T/K?6[Z6Q0B/O88PB1[F,GT_O1E^ZV92^[<S/
M),'V<XCZP.+@G#]Y[Q[VL:7O,-:"7$]@%PWU+F[K]][1[/2L<3X;WLV)=0^L
M_4^NL/3^G8KF-MTL##O>X'\USX8RFIW^$_\`/BZ+ZM="_9&([U2'95Y#KB.`
M!]"EO\FN4>$X,,Q.N/+41#^KW*N,<US&*6,$XL%RED(H2D?T8V__TO54DDDE
M*22224I))))2DDDDE*22224I))))2E'8S=NVC=^]&JDDDI22222E)BUKA!`(
M\"G224L&M:(:`!X!.DDDI__3]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9
M_^T23E!H;W1O<VAO<"`S+C``.$))300E```````0````````````````````
M`#A"24T#[0``````$`!(`````0`!`$@````!``$X0DE-!"8```````X`````
M````````/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))
M30/S```````)```````````!`#A"24T$"@```````0``.$))32<0```````*
M``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8`
M`0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````!@``
M`````3A"24T#^```````<```_____________________________P/H````
M`/____________________________\#Z`````#_____________________
M________`^@`````_____________________________P/H```X0DE-!```
M``````(``3A"24T$`@``````!``````X0DE-!`@``````!`````!```"0```
M`D``````.$))300>```````$`````#A"24T$&@`````#/0````8`````````
M`````$@```"H````!`!L`&\`9P!O`````0`````````````````````````!
M``````````````"H````2``````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````2`````!29VAT;&]N9P```*@````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`$@`````4F=H=&QO;F<```"H`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))300H```````,`````3_P````````.$))3004```````$
M`````CA"24T$#``````,A@````$```"@````10```>```(%@```,:@`8``'_
MV/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2`
M`````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04
M#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,_\``$0@`10"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!````
M``````,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+
M$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("
M`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1
M`#\`]50<W+IPL._,OD4XU;[;($G:QIL?M']5JY_Z^T=<_8YZAT3+NQ\C!W66
MTTD?I:3_`#WM<UWZ:G;ZM7_7:_\`"+SCI?UTZK]K;7UK.MS.DY378^=6\C^9
MN'IOOK]-F[?3N]7V_F*7'A,X\0.VX_28YY!$@'KL78;_`(W>L?;?6=A8_P!@
MF3C@O];9_P"&=WI>K_Z#[/\`JUZABY-67BTY5!W4Y#&VUNXEKP'L/^:Y>7_^
M-+U`94/ZC0.ECW')@BWT^?H?S#7[/\+ZOIK'ZK]=^K.S+/V/FVX/2<=K:<*F
MN(%%0].NQWJ,<_?=M]3_`,#4LL4,E#%6GS+!.4+]SJ='VU)>>95GUFZ1_B^R
M.J=0ZC>.J9+J+&EQ`-%;K:V,I'M_G7U/_6/^V_\`!KB/^>WUG_\`+F_[V?\`
MI-1QY<RNI#0TOEE$:L'5]Z27A`^N7UK(D=7R"#WEG_I-1/UU^M`,'K&0".02
MS_TFG?=)]PM^\1[%]Y27@[?KI]:7?1ZQD&/`L_\`2:[7_%AUSK'4\_J%?4<R
MW+9554ZL6$0"YUH<1M:W]U-GR\H1,B1HF.:,CPT7T-))!S'.9B7N82US:WEK
MAR"&G50@6:9":!/9,DN6^I'4<_..9]LO??Z8JV;XTW>KNB!^=M74I^7&<<S`
MFR*V\?4QX,PS8XY(@@2O?^J>%222Y?ZUN^L(S*?V3]H]+TCO]$`MW;N_\O:E
MCAQR$;$;ZRV3FR^U`SX3.OT8:R>H24*MWIMW3N@3/,PIIC(I))))3__0]57B
M?U[^K7[`ZR[T&1T[.W6XL<,/^'Q?^MN.^O\`X%Z]L7,_XQ6=+=]5<D]1);L+
M78A;&_[1Q0*P?I;O=ZO_`'7]92X)F,QVEH6/+`2B?#4/GC_KKF/^IC/J[+O7
M#O0??XX0$LIW3_._]I'_`/=1G_"(_P#B[^K!ZSU7[?E,GIW3W!Q!'MMO'OJI
M_E,I_GKO^M+DC,:<_P`5[A]1;>E6?5?"_93=E+&[;6.(+Q<#^L^M'^$=;[_Z
MG\A6<Q]N!X17&=2PXOUD@9'Y1H'><UKA#@'#P.JCZ-7[C?N"FDJ+:?"/K=_X
MJ^K?^&7?]2Q>L?4>NMWU1Z27-!/V9FI`7D_UN_\`%7U;_P`,N_ZEB]:^HW_B
M0Z3_`.%F*WS'\U#Z?DU\/\Y-YO\`QO-:WIG3=K0/UIW`C_!/5#_%!_REU3_B
M*?\`J[EH_P"-_P#Y,Z;_`.&G?^>K%G?XH/\`E+JG_$4_]7<@/]S'^7Z23_/C
MR?4$#._H61_Q3_\`J2CH&=_0LC_BG_\`4E5H[CS99_*?(O"_5;K.-T?%S\B_
MW/<*6TT@PY[AZW^:QG^$L5M_UR^L`'VC["QN,=0YU=L1_P`?N:S_`**I?4SI
M]69U3?<T/KQ:_4#3J"\D-KG^K[WKT-7N9GBAE-X_<E*C+B-5I\L7+Y''GR<O
M&LIPPCQ"'"+,O5Q<4K<;H/UFQNKS46^AE-&XU$[@X?OU/]N[^4A?6+ZRV]&R
M*:68[;Q:PODO+8@AO[KESG6ZF]#^LM=^*/3KEF0UC=``XEE]8_D/VV?YZL_7
M_P#IV)_Q3O\`JVH1P8SFQD"\>6)EPGH0/E72YO,.7S`D#-@E&!D!\T9'25/:
M/OKJH=?<X5UL;N>XF`!$E<IE?7?)NR/0Z/B&[]USVN<YP'YS<>F'-;_6>I?7
MK-?7AXN$TD,NFRV.[:PW8W_/=O6O]6NEU].Z74-H&1>UMN0_N7.&X,G]VIIV
M-44(8\>(99QXS,D0AL-/TBS9,F7+G.#%+VXXP)9<E<4KE\L(N)5]=>I8MXKZ
MM@[`=88U]3P/WFUY!=ZG^?6NKQ,O'S<=F3C/%E-@EKA^(/[KF_G(/5>FT=3P
MK,6X#W":W]V/'T+&_P!5<M]1,NVO,R>GO/M>TVAO86,(JM_[<:YG_;:)CCRX
MI3A'@GCKBB/EE$JC/+@SPQ9)^[CRWP3(J<9Q_1D__]'U5>+?7WZS_M[JYKQW
MSTW`+F8Y'#W_`$;\K^KIZ='_``7Z3_"KN/\`&/UW,P^F_LKIM5UF7GM(MMI8
MYWI4?1L.YC7?I;_YFO\`Z[9_HUP7U2^J>5UGK5.-E8UM.!3^ERS8Q]8-;3[<
M=I>UG](?^C_XGUE9Y>(B#DETV8,Q)(A'KN6=OU+S*_J;7]8R'>JY_JOH\,-P
MVU7[8_G-WZR__NI9_P`$B?4#ZS?L+K`Q\E^WIW4'-KO)XKM^C1D_R6_X*_\`
MD?I/\$O9'U5OJ=2]@=4YI8YA`+2TC:6%O[NU>'?67ZJYO1NKWX%./=?B'WXM
MC*WV`TN^C6Y[&N_24_S+_P#MQ/QY!E$H3ZZC^7]5$X>V8R@-M"^Z)+DO\7?7
M<S/Z5^S^I5VUYN``P/M8YGJT_1IMW6-;NL9_,W?]N_X5=:JDHF,B#T9P;%OA
M'UN_\5?5O_#+O^I8O6OJ-_XD.D_^%F+ROZV8.>_ZT]5?7BWO8[)<6N;4]P(A
MG#FL7JWU)8^OZI]*98TL>W'8'-<""#YM<K.<CVX?RZ,.$'CF\W_C?_Y,Z;_X
M:=_YZL6=_B@!_:/5#V]"G_J[EJ?XVL?(OZ;TX4567%N2XD5L<\@>F\?F!R\Y
MHHZWCDNQJ<V@N$.-3+F$@=G;&MW)V./%@X;J_P"*,A,<O%1.G1^@D#.UPL@#
M_1/_`.I*\)]3ZS_O=2_]F$[7_68N:"[J1:7-#@?M$$$C=/\`931RU$>L*EGL
M$<$MGT;_`!?O8,G+8?I.KK<WX-+P[_JV+MEYMTO%ZSBOLZE@TOWXCFBRHL=+
MF/W;OT?M]6OV?I-GZ1G\XM9_^,!YJ+680&1P-UDM#OZ@8U[OZBEYGEYY,IEC
MJ6PEK\A:/(\YCP\O&&:\9U,;C+UQXNE-7ZZ1D]?JQZ_<_P!*NDM'[SWO+6_Y
MMC47Z_\`].Q/^*=_U;47ZN=$S\WJ7[:ZJUPAWJ5BP;7/L_,?Z?\`@Z:O\%_8
M_P`&H_7RFZS-Q376^P"ITEC2[\]O[H3H2B,V'&"#[49"1Z<4AJQY(3/+\QF,
M3'WYQE&)^;@C+TZ+?7ZI^_"M@[75/9Y2-KO^_+K>G7LR,#&OK,LLJ8X?-H57
MK/2*^K=-.,2&6MA]%A_->!W_`)+OH/7*8'6NK?5DG!SL8NHDEC'G;!.KOL]T
M/K?6[Z6Q0B/O88PB1[F,GT_O1E^ZV92^[<S/),'V<XCZP.+@G#]Y[Q[VL:7O
M,-:"7$]@%PWU+F[K]][1[/2L<3X;WLV)=0^L_4^NL/3^G8KF-MTL##O>X'\U
MSX8RFIW^$_\`/BZ+ZM="_9&([U2'95Y#KB.`!]"EO\FN4>$X,,Q.N/+41#^K
MW*N,<US&*6,$XL%RED(H2D?T8V__TO54DDDE*22224I))))2DDDDE*22224I
M))))2E'8S=NVC=^]&JDDDI22222E)BUKA!`(\"G224L&M:(:`!X!.DDDI__3
M]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9.$))300A``````!3`````0$`
M```/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$@!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P````$`.$))300&```````'
M``0````!`0#_X1?Y:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP
M86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y
M9"<_/@H\>#IX;7!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAM
M<'1K/2=835`@=&]O;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\<F1F
M.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M
M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED
M.C`S.#`P860R+39A,&4M,3%D9"UA8C`S+3@R,&%B-C0W868Y82<*("!X;6QN
M<SIE>&EF/2=H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R<^"B`@/&5X
M:68Z0V]L;W)3<&%C93XQ/"]E>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX
M96Q81&EM96YS:6]N/C$V.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X
M:68Z4&EX96Q91&EM96YS:6]N/C<R/"]E>&EF.E!I>&5L641I;65N<VEO;CX*
M(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2=U=6ED.C`S.#`P860R+39A,&4M,3%D9"UA8C`S+3@R,&%B-C0W868Y
M82<*("!X;6QN<SIP9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\G
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70])W5U:60Z,#,X,#!A9#(M-F$P92TQ,61D+6%B,#,M.#(P86(V-#=A
M9CEA)PH@('AM;&YS.G!H;W1O<VAO<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W`O,2XP+R<^"B`@/'!H;W1O<VAO<#I(:7-T;W)Y/CPO<&AO=&]S
M:&]P.DAI<W1O<GD^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP,S@P,&%D,BTV83!E+3$Q9&0M86(P
M,RTX,C!A8C8T-V%F.6$G"B`@>&UL;G,Z=&EF9CTG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]T:69F+S$N,"\G/@H@(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z
M3W)I96YT871I;VX^"B`@/'1I9F8Z6%)E<V]L=71I;VX^-S(O,3PO=&EF9CI8
M4F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXW,B\Q/"]T:69F.EE2
M97-O;'5T:6]N/@H@(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S
M;VQU=&EO;E5N:70^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP,S@P,&%D,BTV83!E+3$Q9&0M86(P
M,RTX,C!A8C8T-V%F.6$G"B`@>&UL;G,Z>&%P/2=H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O)SX*("`\>&%P.D-R96%T941A=&4^,C`P."TP."TQ-%0Q
M,#HS-#HS,2TP-3HP,#PO>&%P.D-R96%T941A=&4^"B`@/'AA<#I-;V1I9GE$
M871E/C(P,#@M,#@M,314,3`Z,S0Z,S$M,#4Z,#`\+WAA<#I-;V1I9GE$871E
M/@H@(#QX87`Z365T861A=&%$871E/C(P,#@M,#@M,314,3`Z,S0Z,S$M,#4Z
M,#`\+WAA<#I-971A9&%T841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!9&]B
M92!0:&]T;W-H;W`@0U,@5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@/"]R
M9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M)W5U:60Z,#,X,#!A9#(M-F$P92TQ,61D+6%B,#,M.#(P86(V-#=A9CEA)PH@
M('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO
M)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z
M,#,X,#!A9#$M-F$P92TQ,61D+6%B,#,M.#(P86(V-#=A9CEA/"]X87!-33I$
M;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70])W5U:60Z,#,X,#!A9#(M-F$P92TQ,61D+6%B,#,M
M.#(P86(V-#=A9CEA)PH@('AM;&YS.F1C/2=H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R<^"B`@/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF
M;W)M870^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAM
M<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&24Q%``$!
M```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`
M````245#('-21T(``````````````````/;6``$`````TRU(4"`@````````
M```````````````````````````````````````````````````````18W!R
M=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP=````@0````4
M<EA96@```A@````49UA96@```BP````48EA96@```D`````49&UN9````E0`
M``!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0``
M`_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``!#P```@,9U12
M0P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@
M245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR+C$`````
M````````````````````````````````````````````````````````````
M`%A96B````````#S40`!`````1;,6%E:(`````````````````````!865H@
M````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(```````
M`"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M`````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````
M````````````````````````````````````````````9&5S8P`````````N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="`````````````````````````````&1E<V,`````````
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`
M`````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ``````````````````````````````````!V:65W```````3
MI/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?
MYVUE87,``````````0````````````````````````*/`````G-I9R``````
M0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``
M10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R
M`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!
M,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1
M`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"
MH@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6
M`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$
MQ`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86
M!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'
MK`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED
M"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+
M:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.
M#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0
M"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C
M$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5
MFQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO
M&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<
M*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_
M'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0C
MPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<
M*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL
M;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2
M,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV
M-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK
M.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!
M*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P
M1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-
M2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J
M4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:
MIEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B
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M9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--
MD[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<
M]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+
MIOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6P
MZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LN
MNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&
M1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\
MT;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=
M$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\
MZ4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U
M4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D
M;V)E`&0``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$'!P<-#`T8$!`8
M%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`2`"H`P$1``(1`0,1`?_=``0`%?_$`:(````'`0$!
M`0$```````````0%`P(&`0`'"`D*"P$``@(#`0$!`0$``````````0`"`P0%
M!@<("0H+$``"`0,#`@0"!@<#!`(&`G,!`@,1!``%(1(Q05$&$V$B<8$4,I&A
M!Q6Q0B/!4M'A,Q9B\"1R@O$E0S13DJ*R8W/"-40GDZ.S-A=49'3#TN(()H,)
M"A@9A)1%1J2T5M-5*!KRX_/$U.3T976%E:6UQ=7E]69VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W.$A8:'B(F*BXR-CH^"DY25EI>8F9J;G)V>GY*CI*6FIZBIJJ
MNLK:ZOH1``("`0(#!04$!08$"`,#;0$``A$#!"$2,4$%41-A(@9Q@9$RH;'P
M%,'1X2-"%5)B<O$S)#1#@A:24R6B8[+"!W/2->)$@Q=4DP@)"A@9)C9%&B=D
M=%4W\J.SPR@IT^/SA)2DM,34Y/1E=865I;7%U>7U1E9F=H:6IK;&UN;V1U=G
M=X>7I[?'U^?W.$A8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZ
MRMKJ^O_:``P#`0`"$0,1`#\`]4XJMDD2.-I)#Q1`69CV`%2<5?,>N?\`.6>O
MC79#HNE6AT2*0K&MSZAGFC!IS+*RK%S&ZKP?C_E9M8=G"MSZG6SUQO8;/H/R
M5YLL/-OE>P\P6*M'!?1\C"Y!:-U)21&I_(ZLN:[+C,)&)<_',2%A.\K9NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__0[1^=9\]VOE&36/)VH26E
MYI?*:\MDCBD]:VI^\($B/\<5/4'']GG_`).9&FX#*I#8M&HXN&XGD^=O+W_.
M0WYA0:U:2:]JC:EHA?AJ-DT,"\X''&3B41&Y*IY)\7VLV<]%"O2*DZ^&KG>Y
MV3/4/^<8O.,VIH_ERZL[_P`NWE)K'49)N!%O)\2&1.)9CP/6/ER_R<C'7QKU
M;292T4B=OI6>;_S)USR"]EY%\DZMZ5IY?B:'4KY(XG^LWTCF2<@2*_%(V/!0
M/\K''@&2YS'U?[E<N8XZC$_2]#_(WS!^:7F33=5\S>8-9EET>VAFBT^`Q0()
MKA5):2JQJW"'[/7XI/\`4S&U4,<2(Q&[D::<Y`R)V>-+_P`Y`?F[Q'_.Q/T_
MWQ;?]4LS?R>+N<,ZK)WM_P#*_P#\W?\`J8G_`.1%M_U2Q_)XNY'YK)WN_P"5
M_?F[_P!3$_\`R(MO^J6/Y/%W+^:R=[7_`"O_`/-S_J8G_P"1%M_U2Q_)XNY?
MS63O<?S^_-ZA_P"=BD_Y$6W_`%2Q_)XNY1JLG>^U=/D>6PMI)#R=XD9V\25!
M)S1GF[D<E?`EYW^<7FC7=!MM+?2;HVK3O*LQ"HW(*JD?;#=*YM.R]/#*9<8N
MJ>?[?UN7!&!QGAXB67^5+RYO?+.EWET_J7%Q:Q232$`<G9`2:"@ZY@ZB`CDD
M!R$B[;19#/#"4OJE&,DURERG8J\I?S'YZ'YF_H\27/Z#^NK'Q]`>EZ5!7]YP
M^S_E<LW(P8/RW%MXG#_.>9EJM5^=X/5X/'_-]/#_`%J>K9IGIG8J[%78J__1
M]4LH8%6%5.Q!Z$8J^+/SV_+4^2O-SR64970=6+7&G$#X8VK66#_GF35/^*V7
M^7-[I,_''?Z@Z?58>"5CD61>0OS\G\O?E5J6A2N6URRI#Y><@G]U/6I)_P"7
M4\G7E]KDB?LY5FTG%D!_A_B;,6JX8$=?X7G'D+R;JGG?S;:Z+;,Q>Y<RWUV?
MB,<(-996)ZMO\/\`-(RYE9LHQQMQL6,SE3[IT?0M+T?1;;1;"!8].M(1!%!U
M'`"AY?S%NK_S9S\I$FSS=W&(`H):/RZ_+\"@\M:7_P!(<'_-&2\:?>?FQ\*'
M<'S[_P`Y4^7M!T>Y\MC2--M=/$R7?K"UACAY\3%QY<`O*E32N;+03,@;-N!K
MH`500_\`SBSH.AZQK/F"/5M/MM0CBMH&B2ZA28(3(X)4.&XDT[8=?.0`HTC1
M1!)L/HB7\N_(/I/3RWI8/$[_`%.#P_U,UOC3[S\W8>%#N#X'FV9P.E3^O.B=
M%U?HEI?_`!S+3_C#'_Q`9S)YO0#DB<"7DWY__P"\>C?\9)_^(IF[[%^J7P>5
M]J?HA[Y?[U%+^:.C^6/*NBV0C:^U(6,#-`C!5CK&*>H^_$G^4+RR'\G3S99'
MZ8\<FW^6<>FP8X_7D\./I_S?XD'IWY^P/,%U#23'$3O)!*'('^JRI7_@LLGV
M+*O3)IQ>U$2?7#A']$\3T[1]8T[6-/BO].F6>VF%5<=01U5@=U8=U.:?+BE"
M7#(47I<&>&6`G`\42QIOS-T]?.'^%_J<QN?7$'UBJ>G4KRK2O+,H:"1P^+8J
MG7'MB`U'@<,N*^'B97>WUI8VDMY>2K!;0J7EE<T50,PX1,B`-R7:9,D81,I'
MAC%YEJWY\Z?%.8M*TU[M`:":9_2#>ZH%=O\`@N.;?'V-(CU2$?\`9/-Y_::`
M-8XF?^Q5-$_/72+F=8=6LGL`QH;A&]9`?\H45P/H;!F['F!<3Q?[%EIO:7'(
MUDB<?]+ZWIL$\-Q"D\#K+#(H:.1""K*14$$9J""#1>DC($6.3__2]4XJPO\`
M.#RKHOF3R#JEMJLR6B6L37EO?R=()85+*Y_R3NCT^TC9?I\AC,$-.>`E`V^%
MQTSH'1OK/_G%K1/+EOY(FU:QE6XUB]F:/5&(H\/I']W`._'B?5Y?M\_\G--K
MY2,Z/)VVCB!&QS>TY@N8[%7S9_SE_P#[U>5O]2\_7#FT[.Y2^#KM?T0W_.(?
M_'=\Q_\`,+;_`/)Q\/:/((T',OIJ;^Z?_5/ZLU0=D_.:;[4GS;]>=.\]U?HE
MI?\`QS+3_C#'_P`0&<R>;T`Y(G`EY-^?W^\FB_\`&2?_`(BF;OL7ZI?!Y7VI
M^B'OE_O49^4'DK2TT*/7+ZV2XOKPL8&E`<1Q*>*\0=@S<:\LK[4U<C,P!J,6
M[L'LZ`Q#+(<4Y_SOX8LN\S^2]#U[3)K6>UB2=E/H7*(JR1O3X6#`5I7[2Y@X
M-7/%($';^:[;6=GXL\#$@7_#+^:\M_);5KK3_--UH4S'TKE9.25V6>W[CYJ&
M'_`YN>UL8GB&0?P_[F3S'L[GECSRPGE+_=P4Y?\`R>0_YCU_Y-#&/^)?YO\`
MOF,O^-3_`#_]ZC?SNU^ZN=4M/+ML28HU6::-?VYI#2-3X\5Z?Z^0['P@1.0_
MB+=[2:F4LD<,?ZTOZTOI>A^2O).E>7-*AB6!'U!E#7=VR@NTA'Q`$[A%Z*N:
MO5:N6:1-^G^&+T'9_9V/3XP`/7_%-`_F)Y$TS7-&N)X+=(M6MT:6WG10K.5%
M3&]/M!Z4%?LMEFAULL4P"?0?J:>UNS(9\9('[R.\9?[UB_Y%>8YY4O-`G<LD
M"_6;,'JJEN,BC_)Y%6_V39F]L8`",@Z^F7^]=9[-:PR$L4OX?5#_`'S_`/_3
M]4XJ^:/^<GOS0^L7`\C:5+^X@*RZW*AV:0?%';[=DVDD_P`O@O[#9M=!@KUG
M_-==K<W\(>1Z-^77F+5O)6L>;K6.NG:.Z)(M#RD!WF9/:!2C2?ZW^3F;+-&,
MQ$\Y.)'`3$R[D[_)'\RW\C^;4>Z<_H+4N,&II4T05_=S@>,1/Q?\5\\JU>#Q
M([?4&>ES<$M^1?:\<D<B+)&P>-P&1U-00=P01XYHG<MXJ^;/^<O_`/>KRM_J
M7GZX<VG9W*7P==K^B&_YQ#_X[OF/_F%M_P#DX^'M'D$:#F7TU-_=/_JG]6:H
M.R?G--]J3YM^O.G>>ZOT2TO_`(YEI_QAC_X@,YD\WH!R1.!+R;\__P#>31?^
M,D__`!%,W?8OU2^#ROM3]$/?+_>LX_+SA_@C1>'V?JJ5^=-_QS7:W^^E?\YW
M?9?^+0_JAD.8I<]X'Y"7UOS<9XS\"W-[)4=.-)!_'.EUFVD`/=#]#PO9F_:!
M(_G9/]\KR_\`D\A_S'K_`,FAD(_XE_F_[YG+_C4_S_\`>J/YAGT?S8CEF($0
MFL7J>@0!*_J.3T(O2T.Z;'M7;M`$\N+'_O7O><T]RME=$B=W-$526)Z4`J<(
M030>$_DD.7G:X9!\`M)C7V,B4SI>US^Y`_I/#>S@O4D_T)?[J+__U.X_G!^8
MT'D7RC-?H5;5KNMOI4!WY3$?;(_DA'QO_L4_;R_38?$E73JTY\O!&WQAHVDZ
MSYJ\R6^G6Q:ZU75KBAE<DDO(2TDKGP7XI';-[*0A&^D731B9RKO?=GE?RCI'
ME[RK:>6[6(/86\'HR!P/WI<'U7<=S*Q9F_ULYZ>0RD9%WD(",:?&?YN_E_+Y
M(\YW6F(I.F7%;G2Y34U@<_8KW:)OW;?[%OVLWNFS>)&^O5T^HQ<$O)[G_P`X
MR_F:=7TAO*&IS<M2TM.6G.YWEM!MPWZM`33_`(Q<?Y,U^OP4>(<I.=H\W$.$
M\P]TS7N:^;/^<O\`_>KRM_J7GZX<VG9W*7P==K^B&_YQ#_X[OF/_`)A;?_DX
M^'M'D$:#F7TU-_=/_JG]6:H.R?G/**R./\H_KSIWG7J$/_.2OYK0PI$EY:!(
MU"*/JJ=%%!WS#_(XW+_.37_]#-?FS_RV6G_2*G]<?R.-?SLU2#\TO-_G=S#Y
M@FAE2Q'.W]&%8J&0T:M.NRYGZ'3QQD\+H.W\\IQA?>7K_P"77YD6^@6*:%YC
M22VCB`>SN>!8"*7XP'"_%Q^+DCKR^%LP]=H#E/B8]_YSD=D]K#!$8L_HKZ)?
MT9>I/?-OYQ^7[;398M#F-[J$JE8G"LL<9(IS8N%KQ[*N8^F[*R2E<_3%S==[
M0880(Q'CF?\`2Q2W\D?*=U!Z_F*]0I]83T;(.-V0D%Y-^S4"K_LLL[7U()&,
M=/J_XEQ_9S02C>:7\7IA_P`4D<O_`)/(?\QZ_P#)H9D1_P`2_P`W_?.#+_C4
M_P`__>LB_.CR;<W]O#K]C&9);2/TKR)!5C""660`;G@2>7^3_JYB]DZL1/AR
MY2^G^L['VA[.ED`RP'JA]?\`4_XZJ>2?SBT5]+@L]?F:UOH%"&Y*LT<H44#5
M0$J]/M?#CJ^RYB1.,<43_L4]G=OXC`1RG@G'^+^<@_S"_-S2[C2I]*\ONT\E
MTIBGO"I1%C848)R`9F8?#]GX<LT/9DA(3R;</\+3VKV[`XSCPGBE/^)-_P`G
M?)MUHNF3:E?QF*]U#B$A;[4<*[KR'9G)Y%?]7*.U-6,DA&/TP_W3E]@=GRP8
MS.>T\G^X?__5]%>9/(/D[S-<0W&OZ5#J,UNAC@:;D>"L:D*`0!4Y9#+*/(TP
MECC+FHZ!^6GD/R_J`U'1=$MK&^5&C6XB4\PK_:`))I7#/-.0HE$<48FP&2Y4
MV)+YE\E>5/,ZP+K^EP:B+4L;?UEJ4YT#4(H=Z#)PRRCR-,)0$N:7:1^5/Y=Z
M/J,&I:7H5M9W]L2T%Q$&5U)!4T/+N#3)RSSD*)V0,,0;`97E+8D?F7R-Y1\S
MM;MK^EPZBUJ&%N9@3P#TY4H1]KBN60RRCR-,)8XRYA;Y:\A^3_+,T\V@:5!I
MTMRJI.\((+JI)4&I/0G&>64N9M8XXQY)\0""#N#L1E;-A)_)/\J"23Y9LZG<
M_"W_`#5E_P"9R=[5X$.YK_E27Y4?]2S9?\"W_-6/YG)WKX$.YW_*DORH_P"I
M9LO^!;_FK'\SD[U\"'<B;/\`*+\M;)G:U\OVL)<`.55A4#Z<E'691RD6G+H<
M.3ZHB5)CK'DCROJ]K#;7U@CI;((K=UJDD:**!5=2&XBG3!BU>3&28GFQU'9^
M#-$1G'Z=HI=IWY4^1K"<3)I_KN*%?K#M*H(W^RQX_>,NR=HYI"N*OZKCX>Q-
M+C-B-_UO4RU5"J%444;`#H!F"[5*3Y2\MG5OTN;"(ZGS]3ZU0\^8%*]?#+OS
M.3@X+]/\UQ?R6'Q/$X1XG\Y-Z"E.V4N4Q75ORP\E:I<&XGT\13L:N]NS0\B>
MY5"%_#,S%VAF@*$MOZ7J=9G['TV4V8[_`-'TJNB_ESY.T>=;BST]3<*:I-,6
ME93_`)/,D+]&#-KLN049;,M-V5I\)N,?5_.EZF2YB.Q?_];U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__7]4XJ[%78J[%78J[%
?78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
